Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable.
作者信息
Dhiman Radha K, Premkumar Madhumita
机构信息
Department of Hepatology Postgraduate Institute of Medical Education and Research Chandigarh India.
Mukh-Mantri Punjab Hepatitis C Relief Fund Punjab Government Punjab India.
出版信息
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):254-261. doi: 10.1002/cld.978. eCollection 2020 Dec.
Abstract
摘要
相似文献
1
Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable.到2030年消除丙型肝炎病毒：攻克“不可能之峰”。
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):254-261. doi: 10.1002/cld.978. eCollection 2020 Dec.
2
Challenges Facing Viral Hepatitis C Elimination in Lebanon.黎巴嫩在消除丙型病毒性肝炎方面面临的挑战
Pathogens. 2023 Mar 9;12(3):432. doi: 10.3390/pathogens12030432.
3
The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?全球丁型肝炎病毒（HDV）流行情况：为采取公共卫生应对措施需要填补哪些空白？
Arch Public Health. 2021 Oct 19;79(1):180. doi: 10.1186/s13690-021-00693-2.
4
5
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.急性丙型肝炎中病毒特异性CD4(+) T细胞应答丧失后丙型肝炎病毒的复发
Gastroenterology. 1999 Oct;117(4):933-41. doi: 10.1016/s0016-5085(99)70353-7.
6
[Physiological aspects of conquering of the Mount Everest].[征服珠穆朗玛峰的生理方面]
Cas Lek Cesk. 1954 Jun 11;93(24):664-6.
7
[Hepatitis C virus: an improbable etiological agent of Gougerot-Sjögren's syndrome].[丙型肝炎病毒：一种不太可能引发干燥综合征的病原体]
Presse Med. 1993 Jun 26;22(23):1108.
8
Role of the specific T-cell response for clearance and control of hepatitis C virus.特异性T细胞反应在丙型肝炎病毒清除和控制中的作用。
J Viral Hepat. 1999 Jul;6 Suppl 1:36-40. doi: 10.1046/j.1365-2893.1999.00006.x.
9
The 11th Canadian Symposium on Hepatitis C Virus: 'Getting back on track towards hepatitis C elimination'.第11届加拿大丙型肝炎病毒研讨会：“重回消除丙型肝炎的正轨”
Can Liver J. 2023 Feb 28;6(1):56-69. doi: 10.3138/canlivj-2022-0034. eCollection 2023 Feb.
10
The Elimination of Hepatitis C as a Public Health Threat.消除丙型肝炎作为公共卫生威胁。
Cold Spring Harb Perspect Med. 2020 Apr 1;10(4):a036939. doi: 10.1101/cshperspect.a036939.
引用本文的文献
1
Early Postnatal Polymerase Chain Reaction Testing in the Identification of Perinatal Transmission of Hepatitis C Virus.出生后早期聚合酶链反应检测在丙型肝炎病毒围产期传播鉴定中的应用
Clin Infect Dis. 2025 Jul 14. doi: 10.1093/cid/ciaf266.
2
Impact of Resistance Associated Substitutions and Predictors of Treatment Failure Following Direct-acting Antiviral Therapy in a Viral Hepatitis C Elimination Cohort.丙型病毒性肝炎消除队列中直接抗病毒治疗后耐药相关替代的影响及治疗失败的预测因素
J Clin Exp Hepatol. 2025 Nov-Dec;15(6):102601. doi: 10.1016/j.jceh.2025.102601. Epub 2025 May 28.
3
Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis.乙型和丙型肝炎病毒感染与多发性骨髓瘤风险：一项系统评价和荟萃分析。
BMC Cancer. 2025 Jun 4;25(1):998. doi: 10.1186/s12885-025-14420-5.
4
Autoantibodies to apolipoprotein A-I in hepatitis C virus infection: a role in disease progression?丙型肝炎病毒感染中抗载脂蛋白A-I自身抗体：在疾病进展中起作用？
Front Immunol. 2025 Mar 20;16:1461041. doi: 10.3389/fimmu.2025.1461041. eCollection 2025.
5
Anonymous Opt-Out HIV and hepatitis C screening at a syringe services program in Florida.佛罗里达州一个注射器服务项目中的匿名退出式艾滋病毒和丙型肝炎筛查。
Harm Reduct J. 2025 Mar 12;22(1):30. doi: 10.1186/s12954-025-01182-3.
6
Outcomes of Low Barrier Hepatitis C Treatment in High Risk Populations From Primary Care.基层医疗中高危人群低门槛丙型肝炎治疗的结果
J Community Hosp Intern Med Perspect. 2024 Nov 2;14(6):10-17. doi: 10.55729/2000-9666.1404. eCollection 2024.
7
Closing the Gaps in Hepatitis C Knowledge Among Internal Medicine Residents in the United States.缩小美国内科住院医师丙型肝炎知识差距
Am J Med Open. 2024 Aug 13;12:100077. doi: 10.1016/j.ajmo.2024.100077. eCollection 2024 Dec.
8
Optimizing Hepatitis C Treatment Monitoring: Is Sustained Virologic Response at 4 Weeks Becoming the New Standard?优化丙型肝炎治疗监测：4周持续病毒学应答会成为新标准吗？
Microorganisms. 2024 Oct 10;12(10):2050. doi: 10.3390/microorganisms12102050.
9
Performance of Elecsys HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection.Elecsys HCV Duo免疫测定法在诊断和评估合并或未合并HIV感染的丙型肝炎患者治疗反应中的性能
Diagnostics (Basel). 2024 Sep 29;14(19):2179. doi: 10.3390/diagnostics14192179.
10
United States Provider Experiences With Telemedicine for Hepatitis C Treatment: A Nationwide Survey.美国医疗服务提供者在丙型肝炎治疗方面使用远程医疗的体验：一项全国性调查。
J Viral Hepat. 2024 Dec;31(12):873-879. doi: 10.1111/jvh.14010. Epub 2024 Oct 1.
本文引用的文献
1
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.《格鲁吉亚实现丙型肝炎消除目标的三年进展，2015 年 4 月至 2018 年 3 月》。
Clin Infect Dis. 2020 Aug 22;71(5):1263-1268. doi: 10.1093/cid/ciz956.
2
Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.印度旁遮普邦全民医保计划中泛基因型索磷布韦-维帕他韦联合方案与基于基因型的直接作用抗病毒药物治疗丙型肝炎患者的真实世界成本效益比较。
PLoS One. 2019 Aug 29;14(8):e0221769. doi: 10.1371/journal.pone.0221769. eCollection 2019.
3
Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view.日本针对乙型和丙型病毒性肝炎的对策：流行病学视角
Hepatol Res. 2019 Sep;49(9):990-1002. doi: 10.1111/hepr.13417. Epub 2019 Aug 22.
4
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.在公共医疗保健环境中，使用通用直接作用抗病毒药物进行去中心化护理，以管理慢性丙型肝炎。
J Hepatol. 2019 Dec;71(6):1076-1085. doi: 10.1016/j.jhep.2019.07.006. Epub 2019 Jul 17.
5
Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.直接作用抗病毒药物时代欧洲丙型肝炎负担和治疗趋势的变化：建模研究。
BMJ Open. 2019 Jun 11;9(6):e026726. doi: 10.1136/bmjopen-2018-026726.
6
The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States.直接作用抗病毒药物对丙型肝炎护理链的影响：确定美国在消除丙型肝炎方面的进展和差距。
Aliment Pharmacol Ther. 2019 Jul;50(1):66-74. doi: 10.1111/apt.15291. Epub 2019 May 22.
7
Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model".丙型肝炎治疗的替代性州级融资——“奈飞模式”
JAMA. 2018 Nov 20;320(19):1977-1978. doi: 10.1001/jama.2018.15782.
8
Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective.直接作用抗病毒治疗在小儿慢性丙型肝炎中的安全性和有效性：公共卫生视角。
J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):74-80. doi: 10.1097/MPG.0000000000002139.
9
Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.澳大利亚丙型肝炎无限制直接抗病毒治疗的真实世界结果：南澳大利亚州的全州经验。
J Viral Hepat. 2018 Nov;25(11):1287-1297. doi: 10.1111/jvh.12943. Epub 2018 Jul 10.
10
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.索磷布韦和维帕他韦治疗近期有注射吸毒史的丙型肝炎病毒感染（SIMPLIFY）：一项开放标签、单臂、4 期、多中心试验。
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.
Zotero 插件